The prognosis of metastatic uveal melanoma (UM) is among the worst of all human cancers.
The identification of near-ubiquitous GNAQ/GNA11 mutations and the activation of MAPK …

Background Uveal melanoma is characterised by mutations in GNAQ and GNA11, resulting
in Ras/Raf/MEK/ERK pathway activation. Treatment with selumetinib (AZD6244, ARRY …

Uveal melanoma is a rare but aggressive subtype of melanoma. Nearly 50% of patients will
develop metastatic disease despite primary enucleation or radiation therapy. There is …

The aim of this study was to test the hypothesis that inhibiting mammalian target of
rapamycin and insulin-like growth factor-1 receptor would be efficacious in metastatic uveal …

Importance Uveal melanoma is characterized by mutations inGNAQandGNA11, resulting in
mitogen-activated protein kinase pathway activation. Objective To assess the efficacy of …

CRA9003 Background: Gq/11 mutations are early oncogenic events in UM resulting in
MAPK pathway activation. We demonstrated decreased viability in UM cell lines harboring …

Background The MAPK pathway is constitutively activated in uveal melanoma (UM), a
disease for which there remains no standard of care for metastatic disease. In a randomised …

Uveal melanoma (UM) is the most common primary intraocular malignancy and the second
most common form of melanoma. UM has a strong tendency for metastatic disease, and no …

Uveal melanoma (UM) comprises approximately 5% of all melanoma diagnoses in the USA
each year. Approximately half of patients with UM eventually develop metastases, most …

Uveal melanoma is an intraocular malignancy that, depending on its size and genetic make-
up, may lead to metastases in up to 50% of cases. Currently, no therapy has been proven to …